Table 4.
Follow up Scheme. N.R.: not recommended; VG: gynecological visit; mo: months; y: years; -: not detailed; LR: low-risk patients; HR: high-risk patients.
| ESGO | NCCN | JSGO | AIOM | FIGO | BGCS | SEOM | ESMO | |
|---|---|---|---|---|---|---|---|---|
| Timing | ESGO Calculator. | VG every 3–6 mo for 2 y; 6–12 mo from 3 to 5 y; then annually. | VG every 3–6 mo for 2 y; every 6–12 for 5 y. | VG every 3–6 mo for 2 y; every 6 mo in next 3 y. | VG every 3–4 mo for 2 y; every 6 mo from 3° to 5°y; then annually for life. | - | LR: every 6 mo for 2 y; HR: every 3 mo for 2 y, then every 6 mo from 3° to 5°y. | VG every 3.6 mo in 2 y; every 6–12 mo until 5°y. |
| Citology | N.R. | N.R. | Suggested as needed. | Annually. | - | - | Only in irradiated pt. | - |
| Imaging | If symptoms. | If symptoms. | Suggested as needed. | If clinical indications. | Involved high pelvic lymph nodes, may justify interval imaging. | Not routinely. | - | Not routinely. |
| Exams | If symptoms. | Semiannual CBCs, blood urea nitrogen (BUN), and serum creatinine determinations. | Suggested as needed. | If clinical indications. | N.R. | - | - | - |
| FU in FSS | HPV test (6–12–24 mo). | Annual cervical/vaginal cytology, MRI at 6 mo, then annual. | Contraception for 6 mo; PMA counseling. | - | - | - | - | - |
| Other | Histology if recurrence suspected. | - | HRT recommender. | In previous RT-CHT-treated, limited pelvic examination, imaging and blood tests (including CEA, CA 125, CA 19.9, AFP, etc.). | - | - | - | - |